WO2024023585 - UROLITHIN AND FLUORENE DERIVATIVES FOR INHIBITING FERROPTOSIS
National phase entry:
Publication Number
WO/2024/023585
Publication Date
01.02.2024
International Application No.
PCT/IB2023/000609
International Filing Date
26.07.2023
Title **
[English]
UROLITHIN AND FLUORENE DERIVATIVES FOR INHIBITING FERROPTOSIS
[French]
DÉRIVÉS D'UROLITHINE ET UTILISATIONS THÉRAPEUTIQUES ASSOCIÉES
Applicants **
VANDRIA SA
Inventors
SENNHENN, Peter, C.
OUMOUCH, Said
ANDREUX, Penelope
Priority Data
63/392,611
27.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2958 | |
| EPO | Filing, Examination, Granting | 18043 | |
| Japan | Filing, Examination, Granting | 2667 | |
| South Korea | Filing, Examination, Granting | 3055 | |
| USA | Filing, Examination, Granting | 6940 |
Total:
33,663
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The application relates to urolithin and fluorene derivatives of the general Formulae (I) and (II), to pharmaceutical compositions comprising them, and to methods useful for inhibiting ferroptosis in a subject in need thereof. The compounds are useful for the treatment of inflammatory diseases, neuronal diseases or neurodegenerative diseases at least partially mediated by ferroptosis.[French]
L'invention concerne des composés, des compositions et des procédés utiles à l'inhibition de la ferroptose chez un sujet en ayant besoin.